시장보고서

상품코드

2077252

진행성 가족성 간내 담즙 정체증 2형 치료 시장 : 약물별, 유통 채널별, 지역별

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, By Distribution Channel, and By Region

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,637,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,325,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,751,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

진행성 가족성 간내 담즙 정체증 2형 치료 시장은 2026년에 2억 1,600만 달러로 추정되며, 2033년에 22억 7,710만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 40.0%로 성장할 것으로 예측됩니다.

보고서 범위		보고서 상세
기준 연도:	2025년	2026년 시장 규모:	2억 1,600만 달러
과거 데이터 기간:	2020-2024년	예측 기간:	2026-2033년
2026-2033년까지 예측 기간의 CAGR:	40.00%	2033년 시장 규모 예측:	22억 7,710만 달러

진행성 가족성 간내 담즙 정체증 2형(PFIC2)은 간에 영향을 미치는 희귀 질환입니다. 이 질환을 앓는 사람들은 일반적으로 영아기에 징후나 증상이 나타나며, 그 중에는 심한 가려움증, 황달, 문맥 고혈압(간으로 혈액을 공급하는 정맥의 고혈압), 간비대(간과 비장의 비대) 등이 포함됩니다. PFIC2는 일반적으로 생후 몇 년 이내에 간부전으로 진행됩니다. 또한, 환자는 간세포암(간암의 일종)에 걸릴 위험이 높아집니다. PFIC2는 ABCB11 유전자의 변이로 인해 발생하며, 상염색체 열성 유전 방식으로 유전됩니다. 치료법으로는 간 손상을 예방하기 위한 우르소데옥시콜산 요법, 수술, 또는 간 이식 등이 있습니다. PFIC에는 PFIC1, PFIC2, PFIC3의 세 가지 유형이 알려져 있습니다.

시장 역학

진행성 가족성 간내 담즙 정체 2형에 대한 인식이 높아짐에 따라, 가까운 시일 내에 PFIC2 치료 시장 관계자들에게 더 많은 기회가 생길 것으로 예상됩니다. 예를 들어, 2019년 10월 3일, 신규 담즙산 조절제를 개발 중인 임상 단계의 희귀 소아 간 질환 전문 기업인 Albireo Pharma, Inc.는 ‘PFIC 인식의 날’에 대한 지원을 발표하며, 진행성 가족성 간내 담즙 정체증(PFIC)을 앓고 있는 환자와 그 가족을 위한 노력을 재차 표명했습니다.

그러나 저·중소득국의 경제 성장이 가속화되었음에도 불구하고, 의료비 지출 격차는 해소되지 않았으며, 의료비 지출에 있어 전 세계적인 불평등은 대체로 변함없이 유지되고 있습니다. 예를 들어, 2015년 WHO가 발표한 보고서 '보편적 의료보장을 위한 세계 의료비 지출에 관한 새로운 전망'에 따르면, 세계 인구의 불과 16%를 차지하는 고소득 국가들이 전 세계 의료비 지출의 80%를 차지하고 있습니다. 대조적으로, 세계 인구의 76%는 중소득 국가에 거주하고 있지만, 이들 국가가 전 세계 의료비 지출에서 차지하는 비중은 20% 이하에 그치고 있습니다. 인구가 5억 명 이상인 저소득 국가들은 2015년 전 세계 의료비 지출의 1% 미만을 차지했을 뿐이었습니다. 따라서 저소득 국가에서 의료비 지출이 적은 것은 희귀질환 치료에 대한 연구 개발을 제약하는 요인이 되고 있습니다.

본 조사의 주요 특징:

본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
본 조사에서는 다음의 매개변수를 바탕으로 전 세계 진행성 가족성 간내 담즙 정체증(II형) 치료 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 개발 및 전략입니다.
본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 정부의 정책, 기술 업그레이드, 시장 확대, 마케팅 전략에 관해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
본 ‘세계 진행성 가족성 간내 담즙 정체증(PFIC) 2형 치료 시장’ 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체는 물론, 조사 컨설팅 회사, 신규 진입 기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 216.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	40.00%	2033 Value Projection:	USD 2,277.1 Mn

Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare condition that affects the liver. People with this condition generally develop signs and symptoms during infancy, which may include severe itching, jaundice, portal hypertension (high blood pressure in the vein that provides blood to the liver) and hepatosplenomegaly (enlarged liver and spleen). PFIC2 generally progresses to liver failure in the first few years of life. Affected people also have an increased risk of developing hepatocellular carcinoma (a form of liver cancer). PFIC2 is caused by change (mutations) in the ABCB11 gene and is inherited in an autosomal recessive manner. Treatment options include ursodeoxycholic acid therapy to prevent liver damage, surgery, and/or liver transplantation. There are three known types of PFIC: PFIC1, PFIC2, and PFIC3.

Market Dynamics

Increasing awareness about progressive familial intrahepatic cholestasis type 2 disease is expected to provide more opportunities for players in the progressive familial intrahepatic cholestasis type 2 treatment market in the near future. For instance, on October 3, 2019, Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced its support for PFIC Awareness Day and reaffirmed its commitment to patients and families living with progressive familial intrahepatic cholestasis (PFIC).

However, higher economic growth in low- and middle-income countries has not closed the gap in health spending, and global inequity in health spending has remained largely unchanged. For instance, according to a report on 'New Perspectives on Global Health Spending for Universal Health Coverage' by WHO published in 2015, high-income countries with only 16% of the world's population, account for 80% of global health spending. Conversely, 76% of the world's population live in middle-income countries, but these account for less than 20% of global health spending. Low-income countries, with more than half a billion people, accounted for less than 1% of the world's health spending in 2015. Thus, low healthcare spending in low income countries limits such countries for research and development of new drugs for treatment of rare diseases.

Key features of the study:

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global progressive familial intrahepatic cholestasis type 2 treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc. and Mirum Pharmaceuticals
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global progressive familial intrahepatic cholestasis type 2 treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for progressive familial intrahepatic cholestasis type 2 treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug (Revenue, USD Mn, 2021 - 2033)
Ursodeoxycholic acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Europe
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Asia Pacific
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
- By Drug:
  - Ursodeoxycholic acid
  - Cholestyramine
  - Rifampicin
  - Late Stage Pipeline Drugs
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Company Profiles
Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
AbbVie, Inc.
Glenmark Pharmaceuticals Limited
Par Pharmaceuticals, Inc.
Mylan N. V.
Sanofi S.A.
Novartis International AG
Akorn, Inc.
Albireo Pharma, Inc.
Mirum Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Recent Trends & Key Developments
Regulatory Scenario
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Ursodeoxycholic acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Cholestyramine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Rifampicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

5. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)

6. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, Y-o-Y Growth By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country/Region, 2021 -2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Glenmark Pharmaceuticals Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Par Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Akorn, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Albireo Pharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mirum Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Jadeite Medicines Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ipsen Pharma
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Analyst's Views

8. Section

References
Research Methodology
About us and Sales Contact

진행성 가족성 간내 담즙 정체증 2형 치료 시장 : 약물별, 유통 채널별, 지역별